The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT
Age≥18 years old;
Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg/kg) of tenecteplase IVT within 4.5 hours of onset;
Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT;
Tirofiban or placebo treatment can be initiated within 6h after IVT;
Received or plan to undergo bridge therapy;
Large area of infarct indicated by radiological imaging(≥1/3 of middle cerebral artery supply area);
Atrial fibrillation or suspected cardiac embolism;
Accompanied by epileptic seizures;
Parallel
Tirofiban
DrugTirofiban is a selective glycoproteinⅡb/Ⅲa receptor inhibitor, which inhibits platelet aggregation and thrombi formation
Tirofiban simulant
DrugTirofiban simulant is placebo packed the same style as tirofiban
Proportion of patients of modified Rankin Scale (mRS)≤1
mRS depicts functional outcome of stroke, which ranges from 0-6, mRS 0-1 represents excellent functional outcome
Proportion of patients of mRS≤2
mRS depicts functional outcome of stroke, which ranges from 0-6, mRS 0-2 represents favorable functional outcome
Distribution of mRS
mRS depicts functional outcome of stroke, which ranges from 0-6
National Institute of Health stroke scale (NIHSS)
National Institute of Health stroke scale (NIHSS) ranges from 0 to 42, a low value represents a better outcome
Symptomatic intracranial hemorrhage
Symptomatic intracranial hemorrhage is defined according to the ECASS Classification
Hemorrhagic transformation
defined according to the ECASS Classification
Click on the lead sponsor to view all of their trials.
